“Move your money by early 2022,” Wall Street legend warns
A new form of technology will cause a massive shift in the wealth divide in 2022. Do you own the stocks that will be affected?
Details here…
Snehal S. Patel, insider at Greenwich LifeSciences
Snehal S. Patel Insider Alerts

Get notified the next time Snehal S. Patel buys or sells Greenwich LifeSciences stock. Enter your email address below to get our daily insider buying and selling report.

Snehal S. Patel Insider Information

Mr. Patel has over 30 years of experience in executive management, corporate development, operations, and investment banking in the healthcare industry.  He has served as a consultant, manager, and advisor for R&D and manufacturing design, scale-up, and operations at multiple public and private biotech companies, working on clinical and pre-clinical assets in stem cell therapy, multiple sclerosis t-cell therapy, oncolytic viruses, and disposable biotech manufacturing equipment.  Mr. Patel has also served as an investment banker at Sanders Morris Harris, Ferghana Partners, and JP Morgan Chase, where he focused on healthcare and biotech financing and strategic transactions.  Prior to that, he worked in operations and business development at consulting firms and Bayer Corporation.  He received a BS in Chemical Engineering and an MS in Biochemical Engineering from the Massachusetts Institute of Technology, a Certificate in Project Management from the University of California at Berkeley, and an MBA from the University of Chicago.

What is Snehal S. Patel's net worth?

The estimated net worth of Snehal S. Patel is at least $22.46 million as of April 13th, 2021. Mr. Patel owns 1,189,539 shares of Greenwich LifeSciences stock worth more than $22,458,496 as of January 20th. This net worth evaluation does not reflect any other assets that Mr. Patel may own. Additionally, Mr. Patel receives an annual salary of $507,480.00 as CEO at Greenwich LifeSciences. Learn More.

How old is Snehal S. Patel?

Mr. Patel is currently 57 years old. There are 1 older executives and no younger executives at Greenwich LifeSciences. Learn More.

What is Snehal S. Patel's salary?

As the CEO of Greenwich LifeSciences, Inc., Mr. Patel earns $507,480.00 per year.

How do I contact Snehal S. Patel?

The corporate mailing address for Mr. Patel and other Greenwich LifeSciences executives is , , . Greenwich LifeSciences can also be reached via phone at 832-819-3232 and via email at [email protected]

Has Snehal S. Patel been buying or selling shares of Greenwich LifeSciences?

During the last quarter, Snehal S. Patel has bought $48,831.00 in Greenwich LifeSciences stock. Most recently, on Monday, January 3rd, Snehal Patel bought 2,050 shares of Greenwich LifeSciences stock. The stock was acquired at an average cost of $23.82 per share, with a total value of $48,831.00.

Are insiders buying or selling shares of Greenwich LifeSciences?

During the last year, Greenwich LifeSciences insiders bought shares 7 times. They purchased a total of 9,401 shares worth more than $263,592.69. The most recent insider tranaction occured on January, 18th when VP Jaye Thompson bought 500 shares worth more than $9,435.00. Insiders at Greenwich LifeSciences own 68.9 % of the company.

Information on this page was last updated on 1/18/2022.

Snehal S. Patel Insider Trading History at Greenwich LifeSciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/3/2022Buy2,050$23.82$48,831.00View SEC Filing Icon  
12/14/2021Buy1,840$27.17$49,992.80View SEC Filing Icon  
4/13/2021Buy2,700$36.98$99,846.001,189,539View SEC Filing Icon  
11/19/2020Buy2,000$5.40$10,800.001,186,839View SEC Filing Icon  
See Full Table

Snehal S. Patel Buying and Selling Activity at Greenwich LifeSciences

This chart shows Snehal Patel's buying and selling at Greenwich LifeSciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Greenwich LifeSciences Company Overview

Greenwich LifeSciences logo
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Read More

Today's Range

Now: $18.88
Low: $18.51
High: $19.76

50 Day Range

MA: $28.14
Low: $18.87
High: $36.92

2 Week Range

Now: $18.88
Low: $18.51
High: $69.77


40,057 shs

Average Volume

38,188 shs

Market Capitalization

$245.78 million

P/E Ratio


Dividend Yield



Free Pick from Jeff Brown: “Buy S.C.G .”
Jeff Brown picked Tesla in 2018 before it jumped 1,390%. He picked Nvidia before it jumped 3,545%. And he picked Bitcoin before it skyrocketed 22,750%.

And now he’s saying S.C.G. will be the next big tech play. He’s not the only one. Apple’s CEO even called it “the next big thing.”
Click here and get the name and ticker symbol!